retatrutide clinical trial results 2024 2025 press release Lilly's triple agonist achieves 16.8% weight loss in phase 3 retatrutide clinical trial results 2024

Tirzepatide is a dual agonist, meaning it mimics two hormones: GLP-1 and GIP

Timing: Generally recommended to take before exercise or shortly before eating

GLP-1 Market Size and Forecast 2026 to 2035 The global GLP-1 market size accounted for USD 58.40 billion in 2025 and is predicted to increase from USD 66.46 billion in 2026 to approximately USD 212.73 billion by 2035, expanding at a CAGR of 13.80% from 2026 to 2035

Please see this article for more information

If you typically take other medications in the morning, insulin, or medications that must be taken with food, you'll need to delay them by at least 30 minutes